Aypak Cenk, Bircan Mustafa A, Özdemir Ayşe
Department of Family Medicine, University of Health Sciences, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
Rambam Maimonides Med J. 2022 Jul 31;13(3):e0017. doi: 10.5041/RMMJ.10473.
Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rates among those particularly vulnerable patients.
This cross-sectional study followed the medical records of patients with OF starting from their first OF diagnosis date. Each patient's preventive osteoporosis treatments (vitamin D, calcium+vitamin D) and AOD utilization rate were recorded for a 12-month period following OF diagnosis.
A total of 210 patients (168 females, mean age: 67.8±11.9 years; 42 males, mean age 62.4±16.1 years) were enrolled in the study. Of these, 65.7% (n=138) did not use any medication for primary protection against osteoporosis before OF diagnosis. The ratio of patients not using any type of medication for secondary prevention after OF increased from 26.5% to 51% during a 12-month period. In addition, by one year following diagnosis, AOD usage rate had decreased from 62.3% to 41.3%.
The AOD usage rates for secondary prevention of OF were insufficient, and cessation rates were high. Identification of factors associated with decreased AOD utility rates will provide important information for guiding patient follow-up in order to reduce the occurrence of OF.
抗骨质疏松药物(AOD)对于已确诊骨质疏松症患者预防骨质疏松性骨折(OF)至关重要。然而,关于OF患者中AOD使用率的数据却很少。因此,本研究旨在确定这些特别脆弱患者中的AOD使用率。
这项横断面研究从首次诊断OF之日起跟踪OF患者的病历。记录每位患者在OF诊断后的12个月内预防性骨质疏松治疗(维生素D、钙+维生素D)及AOD使用率。
本研究共纳入210例患者(168例女性,平均年龄:67.8±11.9岁;42例男性,平均年龄62.4±16.1岁)。其中,65.7%(n = 138)在OF诊断前未使用任何药物进行骨质疏松的一级预防。在12个月期间,OF后未使用任何药物进行二级预防的患者比例从26.5%增至51%。此外,到诊断后一年,AOD使用率从62.3%降至41.3%。
OF二级预防的AOD使用率不足,停药率较高。识别与AOD使用率降低相关的因素将为指导患者随访提供重要信息,以减少OF的发生。